WO 2004/053087 PCT/US2003/038970

What is claimed is:

1. 5-(4-fluoro-phenyl)-2-ureido-thiophene-3-carboxylic acid amide, also having the structure:

5

- 2. A method of treating a disease characterized by pathological NF-kB activation comprising inhibiting the pathological activation by administering to a patient in need thereof an effective amount of a compound according to claim 1.
- 10 3. A method according to claim 2 wherein the disease is an inflammatory or tissue repair disorder.
- 4. A method according to claim 3 wherein the disease is selected from the group consisting of inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis, osteoporosis and fibrotic diseases, dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage, autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection,
  20 Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including aquired immune deficiency syndrome (AIDS),
- 25 5. A method according to claim 3 wherein said disease is dermatosis.

adult respiratory distress syndrome, and Ataxia Telangiestasia.

WO 2004/053087 PCT/US2003/038970

6. A method according to claim 3 wherein the disease is selected from the group consisting of: psoriasis, atopic dermatitis, and UV-induced skin damage.

- A method according to claim 3 wherein he disease is selected from the group
   consisting of autoimmune diseases; tissue and organ rejection, Alzheimer's disease,
   stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, osteoarthritis,
   osteoporosis, and Ataxia Telangiestasia.
- A method according to claim 3 wherein said disease is an autoimmune
   disease.
  - 9. A method according to claim 3 wherein the autoimmune disease is systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, or alkylosing spondylitis, diabetes
- 15 10. A method according to claim 3 wherein the disease is cancer and or cachexia.
  - 11. A method according to claim 3 wherein the cancer is Hodgkins disease.
- 12. A method according to claim 3 wherein the disease is inflammation
   20 associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS).
  - 13. A method according to claim 3 wherein the disease is AIDS.
- 25 14. A method according to claim 3 wherein the disease is adult respiratory distress syndrome.
  - 15. A method according to claim 3 wherein said disease is COPD.
- 30 16. A method according to claim 3 wherein said disease is asthma.

WO 2004/053087 PCT/US2003/038970

17. A method according to claim 3 wherein said disease is rheumatoid arthritis.

18. A method according to claim 3 wherein there is dual inhibition of NF-kB and checkpoint kinase.

5